Pershia Davoodi Karsalari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pershia Davoodi Karsalari has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Nima Rezaei
Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center Tehran University of Medical Sciences Tehran Iran
2 shared publications Noosha Samieefar
2 shared publications- Parinaz Alizadeh
Network of Interdiciplinarity in Neonates and Infants (NINI) Universal Scientific Education and Research Network (USERN) Tehran Iran
2 shared publications - Ali Hajihashemi
Department of Radiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
1 shared publication - Aslan Ahmadi
Ear Nose Throat (ENT) and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication Aylar Mohammadi
Network of Interdiciplinarity in Neonates and Infants (NINI) Universal Scientific Education and Research Network (USERN) Tehran Iran
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by Beilstein Institut in Beilstein Journal of Nanotechnology
- Vol. 17 (1) , 1516-1548
Biocompatible nanoscale contrast agents for MRI and CT scans: current progress and clinical potential
Conventional contrast agents for magnetic resonance imaging (MRI) and computed tomography (CT) have long served as the backbone of diagnostic imaging. Yet, their well-recognized limitations, including nephrogenic systemic fibrosis and progressive gadolinium deposition with Gd-based chelates, contrast-induced nephropathy with iodinated agents, and serious hypersensitivity reactions with approved iron oxide formulations, continue to drive the search for safer alternatives. Nanoparticle-based contrast agents (NCAs) have emerged as a compelling next generation of imaging tools, offering a degree of rational design simply not achievable with small-molecule agents. By independently tuning core composition, hydrodynamic size, surface chemistry, and morphology, NCAs can be engineered to enhance relaxivity or X-ray attenuation, extend vascular residence time, direct clearance toward renal or hepatobiliary pathways, and carry targeting ligands for site-specific delivery. This review covers the principal NCA classes, iron oxide nanoparticles, gadolinium- and manganese-based nanomaterials, gold and copper nanostructures, carbon dots, lanthanide-doped upconversion nanocrystals, and quantum dots, examining their physicochemical design, pharmacokinetics, biocompatibility, and diagnostic performance across oncological and vascular applications. A recurring theme is the central role of size: Particles below the ≈6 nm glomerular filtration threshold undergo renal excretion and exhibit lower bioaccumulation risk, while larger formulations follow hepatobiliary routes with implications for long-term tissue retention. Surface coating, protein corona formation, and mononuclear phagocyte system recognition are discussed as equally decisive determinants of in vivo behavior, often outweighing core composition in their influence on clearance and tolerability. Across material classes, preclinical evidence consistently shows favorable safety profiles for well-engineered NCAs, with minimal hemolysis, low immunogenicity, and absence of histological organ injury at imaging-relevant doses, a meaningful contrast to the adverse effect profiles of conventional agents. On the efficacy side, targeted NCA formulations have demonstrated promising results across multiple tumor types, including breast, brain, liver, lung, and renal cancers, with receptor-specific designs enabling molecular-level lesion characterization that conventional agents cannot provide. Multimodal and theranostic constructs, combining MRI or CT contrast with concurrent therapeutic function, further illustrate the flexibility that nanoparticulate platforms offer. Blood–brain barrier penetration for neurooncological applications and the emerging potential of magnetic particle imaging as a future translational direction for platforms based on superparamagnetic iron oxide nanoparticles are also discussed. The translational gap between preclinical promise and clinical reality remains the field’s most honest challenge, rooted in the scarcity of long-term human safety data, the lack of standardized preclinical evaluation frameworks, and the demanding requirements of good-manufacturing-practice production at scale. Addressing these gaps, through unified safety pipelines, harmonized reporting standards, and early-phase trials that connect imaging performance to clinical outcomes, is what will ultimately determine whether NCAs fulfill their considerable potential in diagnostic medicine.
- 2 November 2026
- Published by Beilstein Institut in Beilstein Journal of Nanotechnology
- Vol. 17 (1) , 1516-1548
Open AccessBiocompatible nanoscale contrast agents for MRI and CT scans: current progress and clinical potential
Conventional contrast agents for magnetic resonance imaging (MRI) and computed tomography (CT) have long served as the backbone of diagnostic imaging. Yet, their well-recognized limitations, including nephrogenic systemic fibrosis and progressive gadolinium deposition with Gd-based chelates, contrast-induced nephropathy with iodinated agents, and serious hypersensitivity reactions with approved iron oxide formulations, continue to drive the search for safer alternatives. Nanoparticle-based contrast agents (NCAs) have emerged as a compelling next generation of imaging tools, offering a degree of rational design simply not achievable with small-molecule agents. By independently tuning core composition, hydrodynamic size, surface chemistry, and morphology, NCAs can be engineered to enhance relaxivity or X-ray attenuation, extend vascular residence time, direct clearance toward renal or hepatobiliary pathways, and carry targeting ligands for site-specific delivery. This review covers the principal NCA classes, iron oxide nanoparticles, gadolinium- and manganese-based nanomaterials, gold and copper nanostructures, carbon dots, lanthanide-doped upconversion nanocrystals, and quantum dots, examining their physicochemical design, pharmacokinetics, biocompatibility, and diagnostic performance across oncological and vascular applications. A recurring theme is the central role of size: Particles below the ≈6 nm glomerular filtration threshold undergo renal excretion and exhibit lower bioaccumulation risk, while larger formulations follow hepatobiliary routes with implications for long-term tissue retention. Surface coating, protein corona formation, and mononuclear phagocyte system recognition are discussed as equally decisive determinants of in vivo behavior, often outweighing core composition in their influence on clearance and tolerability. Across material classes, preclinical evidence consistently shows favorable safety profiles for well-engineered NCAs, with minimal hemolysis, low immunogenicity, and absence of histological organ injury at imaging-relevant doses, a meaningful contrast to the adverse effect profiles of conventional agents. On the efficacy side, targeted NCA formulations have demonstrated promising results across multiple tumor types, including breast, brain, liver, lung, and renal cancers, with receptor-specific designs enabling molecular-level lesion characterization that conventional agents cannot provide. Multimodal and theranostic constructs, combining MRI or CT contrast with concurrent therapeutic function, further illustrate the flexibility that nanoparticulate platforms offer. Blood–brain barrier penetration for neurooncological applications and the emerging potential of magnetic particle imaging as a future translational direction for platforms based on superparamagnetic iron oxide nanoparticles are also discussed. The translational gap between preclinical promise and clinical reality remains the field’s most honest challenge, rooted in the scarcity of long-term human safety data, the lack of standardized preclinical evaluation frameworks, and the demanding requirements of good-manufacturing-practice production at scale. Addressing these gaps, through unified safety pipelines, harmonized reporting standards, and early-phase trials that connect imaging performance to clinical outcomes, is what will ultimately determine whether NCAs fulfill their considerable potential in diagnostic medicine.
- Open Access
- 1 January 2026
- Published by KEAI Publishing in Advances in Biomarker Sciences and Technology
- Vol. 8, 509-524
The use of machine learning algorithms in the identification of novel biomarkers for disorders of the immune system
- 1 January 2026
- Published by KEAI Publishing in Advances in Biomarker Sciences and Technology
- Vol. 8, 509-524
Open AccessThe use of machine learning algorithms in the identification of novel biomarkers for disorders of the immune system
- Open Access
- 21 November 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (11) , e71463
Cardiac Tamponade During Congenital Diaphragmatic Hernia Repair in an Infant: A Case Report and Literature Review
Intraoperative cardiac tamponade is an exceptionally rare but life‐threatening complication during congenital diaphragmatic hernia repair in infants. In this case, pericardial effusion from inadvertent intravenous fluid extravasation led to cardiovascular collapse. Prompt recognition and pericardiocentesis were lifesaving, emphasizing vigilance when unexplained hemodynamic instability occurs during central or jugular venous access.
- 21 November 2025
- Published by Wiley in Clinical Case Reports
- Vol. 13 (11) , e71463
Open AccessCardiac Tamponade During Congenital Diaphragmatic Hernia Repair in an Infant: A Case Report and Literature Review
Intraoperative cardiac tamponade is an exceptionally rare but life‐threatening complication during congenital diaphragmatic hernia repair in infants. In this case, pericardial effusion from inadvertent intravenous fluid extravasation led to cardiovascular collapse. Prompt recognition and pericardiocentesis were lifesaving, emphasizing vigilance when unexplained hemodynamic instability occurs during central or jugular venous access.
- 4 May 2025
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 29 (4-5) , 281-301
NLRP3 inflammasome: significance and potential therapeutic targets to advance solid organ transplantation
NOD-like receptor (NLR) family pyrin domain-containing 3 (NLRP3) inflammasome, integral to innate immunity, has become a pivotal figure in the inflammatory cascade. This article provides an overview of the NLRP3 inflammasome, reviewing its complicated structure, as well as the diverse signals that trigger its assembly. Furthermore, we explored the intricate relationship between the NLRP3 inflammasome and acute and chronic rejection in solid organ transplantation. Solid organ transplantation stands as a crucial medical intervention, yet its efficacy is challenged by immune-mediated complications, including acute rejection, ischemia-reperfusion injury, and chronic allograft rejection. We also investigated the encouraging potential of immunosuppressive therapies targeting NLRP3 signaling to alleviate inflammatory responses linked to transplantation. In recent years, the NLRP3 inflammasome has garnered considerable attention owing to its critical functions spanning diverse fields. This study highlights the critical function of the NLRP3 inflammasome and presents insights, offering fresh perspectives on how its modulation might help to improve the outcomes among patients who undergo solid organ transplantations.
- 4 May 2025
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 29 (4-5) , 281-301
NLRP3 inflammasome: significance and potential therapeutic targets to advance solid organ transplantation
NOD-like receptor (NLR) family pyrin domain-containing 3 (NLRP3) inflammasome, integral to innate immunity, has become a pivotal figure in the inflammatory cascade. This article provides an overview of the NLRP3 inflammasome, reviewing its complicated structure, as well as the diverse signals that trigger its assembly. Furthermore, we explored the intricate relationship between the NLRP3 inflammasome and acute and chronic rejection in solid organ transplantation. Solid organ transplantation stands as a crucial medical intervention, yet its efficacy is challenged by immune-mediated complications, including acute rejection, ischemia-reperfusion injury, and chronic allograft rejection. We also investigated the encouraging potential of immunosuppressive therapies targeting NLRP3 signaling to alleviate inflammatory responses linked to transplantation. In recent years, the NLRP3 inflammasome has garnered considerable attention owing to its critical functions spanning diverse fields. This study highlights the critical function of the NLRP3 inflammasome and presents insights, offering fresh perspectives on how its modulation might help to improve the outcomes among patients who undergo solid organ transplantations.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Medicine
- Vol. 2025 (1) , 7094069
A Rare Nasopharyngeal Hemangioma Presenting as Recurrent Cyanotic Apnea in a Neonate: A Case Report and Literature Review
Background: Infantile hemangiomas (IHs) are the most common vascular tumors of infancy, but airway involvement is rare and potentially life‐threatening. While subglottic and laryngeal regions are most frequently affected, nasopharyngeal hemangiomas are exceptionally uncommon, particularly in premature infants presenting with nonspecific symptoms such as apnea and cyanosis. Case Presentation: We describe a female infant born prematurely at 35 weeks via cesarean section, who developed recurrent apnea and cyanotic episodes shortly after discharge. Flexible bronchoscopy revealed a nasopharyngeal mass causing upper airway obstruction, and imaging raised suspicion of a hemangioma. The patient underwent surgical excision of the lesion and was started on a tapering course of prednisolone. Postoperative recovery was favorable, and oral propranolol was initiated to prevent recurrence. At follow‐up, the patient demonstrated normal development without respiratory symptoms. Conclusion: Nasopharyngeal hemangiomas are rare and may present subtly in premature infants. Early bronchoscopy and imaging should be considered in cases of unexplained apnea or airway compromise. A multidisciplinary approach ensures timely diagnosis and effective treatment, minimizing long‐term respiratory complications.
- 1 January 2025
- Published by Wiley in Case Reports in Medicine
- Vol. 2025 (1) , 7094069
Open AccessA Rare Nasopharyngeal Hemangioma Presenting as Recurrent Cyanotic Apnea in a Neonate: A Case Report and Literature Review
Background: Infantile hemangiomas (IHs) are the most common vascular tumors of infancy, but airway involvement is rare and potentially life‐threatening. While subglottic and laryngeal regions are most frequently affected, nasopharyngeal hemangiomas are exceptionally uncommon, particularly in premature infants presenting with nonspecific symptoms such as apnea and cyanosis. Case Presentation: We describe a female infant born prematurely at 35 weeks via cesarean section, who developed recurrent apnea and cyanotic episodes shortly after discharge. Flexible bronchoscopy revealed a nasopharyngeal mass causing upper airway obstruction, and imaging raised suspicion of a hemangioma. The patient underwent surgical excision of the lesion and was started on a tapering course of prednisolone. Postoperative recovery was favorable, and oral propranolol was initiated to prevent recurrence. At follow‐up, the patient demonstrated normal development without respiratory symptoms. Conclusion: Nasopharyngeal hemangiomas are rare and may present subtly in premature infants. Early bronchoscopy and imaging should be considered in cases of unexplained apnea or airway compromise. A multidisciplinary approach ensures timely diagnosis and effective treatment, minimizing long‐term respiratory complications.